Company release, Inside information

3 July 2023 at 11:00 a.m. (EEST)

Nightingale Health’s Plc’s (”Nightingale Health”) financial year ended on 30 June 2023. During the financial year 2022 – 2023, Nightingale Health achieved the following business targets communicated in the Financial Statements Release published on 29 September 2022:

Win contract(s) in medical research with more than 175,000 blood samples

  • The demand for Nightingale Health’s service in medical research continues to be strong and the company has won significant new commercial agreements in this sector reaching the target of selling analysis for more than 175,000 blood samples.

Nightingale Health did not achieve the following business targets within financial year 2022 – 2023:

Win a significant commercial contract in the public healthcare sector

  • The negotiations for a commercial contract in the public healthcare sector are progressing. Nightingale Health expects to announce an update regarding the public healthcare sector by the end of calendar year 2023.

Win B2B commercial contract(s) with more than 50,000 blood samples

  • Nightingale Health announced on 30 June 2023 that it has signed a letter of intent with Suomen Terveystalo Oy ("Terveystalo") to expand the strategic partnership. Nightingale Health expects that the expansion of the partnership will significantly increase the blood sample analysis volumes ordered by Terveystalo. Nightingale Health and Terveystalo’s target is to announce the agreement of the expansion of the partnership in September 2023 at the latest.

For further information, please contact:
Teemu Suna, CEO

Certified Adviser:
Oaklins Merasco Ltd. tel. +358 9 6129 670

About Nightingale Health
Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: